IL2 and nonpapillary renal cell carcinoma: Based on the above findings, we speculate that the dual immunomodulatory effects of IL-2 and dysfunctional NK cells influenced by the immunosuppressive tumor microenvironment contribute to the insensitivity of ccRCC to IL-2 treatment.